Zobrazeno 1 - 10
of 36
pro vyhledávání: '"D L Shungu"'
Autor:
Bernd Wiedemann, David M. Livermore, Reinhard Zbinden, Elena Loza, Simone Bagel, John D. Turnidge, Clarence J. Fernandes, Carl-Erik Nord, Fernando Baquero, Marc Struelens, Michael W. Carter, Jacqueline Nguyen, Stefan Pfister, Jan M. Bell, Lorna A. Fernandes, Nicole van den Braak, Caire Nonhoff, Laura S. Rasmussen, Vincent Jarlier, Lori Mixson, D L Shungu, Evangelos J. Giamarellos-Bourboulis, Helen Giamarellou, Hubert P. Endtz, Niels Frimodt-Møller
Publikováno v:
Antimicrobial Agents & Chemotherapy, 45(6), 1860-1867. American Society for Microbiology
Ertapenem (MK-0826, L-749,345) is a 1-β-methyl carbapenem with a long serum half-life. Its in vitro activity was determined by broth microdilution against 3,478 bacteria from 12 centers in Europe and Australia, with imipenem, cefepime, ceftriaxone,
Autor:
Lynn L. Silver, Deborah F. Suber, Marie-France I. Palepou, Elaina Ward, Philip M. Tierno, Katherine Young, Ronald E. Painter, Kenneth Inglima, D L Shungu, David M. Livermore, Luke Tysall, John Kornblum, Neil Woodford
From April 2000 to April 2001, 24 patients in intensive care units at Tisch Hospital, New York, N.Y., were infected or colonized by carbapenem-resistant Klebsiella pneumoniae . Pulsed-field gel electrophoresis identified a predominant outbreak strain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ef05b526814842804d89d990c5b0b99
https://europepmc.org/articles/PMC529220/
https://europepmc.org/articles/PMC529220/
Publikováno v:
Clinical therapeutics. 13(1)
The susceptibility of 293 cultures of Escherichia coli and 160 cultures of Klebsiella species isolated consecutively from patients in intensive care units at 25 New York area hospitals to four antibiotic agents was determined. Susceptibility testing
Publikováno v:
Dalton Transactions: An International Journal of Inorganic Chemistry; 8/7/2024, Vol. 53 Issue 29, p12080-12089, 10p
Autor:
Barbara Weissberger, Hans H. Gadebusch, D L Shungu, Larry Koupal, Ellen Weinberg, Edward O. Stapley, Vicki Tutlane, Mary E. Valiant
Publikováno v:
Applied and Environmental Microbiology. 46:840-845
GELRITE gellan gum (formerly known as PS-60 and S-60) is a new naturally derived, highly purified polysaccharide which displays several interesting properties, including selfgelling. The suitability of GELRITE as an agar substitute was tested by eval
Publikováno v:
Antimicrobial Agents and Chemotherapy. 23:86-90
A comparison was made of the in vitro activities of norfloxacin and of nine other orally administered antibacterial agents against 180 clinical isolates representing the bacterial species most frequently implicated in infections of the gastrointestin
Autor:
D L Shungu, Mary E. Valiant, Barbara Weissberger, Hans H. Gadebusch, Robert A. Fromtling, Suzanne Ponticas, Charles Gill, George K. Abruzzo
Publikováno v:
The Journal of Antibiotics. 42:795-806
The in vitro antibacterial spectrum of L-658,310, a new semisynthetic cephalosporin, was compared with ceftazidime, aztreonam and piperacillin against a wide variety of randomly selected human clinical isolates. The compound was found to be a broad s
Publikováno v:
Journal of Bacteriology. 138:598-608
Three autolytic-defective mutants of Streptococcus faecium (S. faecalis ATCC 9790) were isolated. All three autolytic-defective mutants exhibited the following properties relative to the parental strain: (i) slower growth rates, especially in chemica
Publikováno v:
Infection. 10:41-44
425 randomly selected, fresh clinical isolates were tested for susceptibility to norfloxacin and other orally absorbed agents, i.e. amoxicillin, ampicillin, carbenicillin (available commercially as the indanyl ester), cefaclor, cinoxacin, erythromyci
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 8:626-628
The in vitro activity of seven antibiotics against 52 isolates of Neisseria gonorrhoeae was determined. Against penicillinase-producing Neisseria gonorrhoeae, ceftriaxone was the most active agent (MIC90 0.015 micrograms/ml), followed by ceftizoxime